EternaGen / NAD 007-013Research compound · Research use only
NAD+
A coenzyme every cell uses to transfer energy and support core metabolic reactions.
Purchasing review required
Can’t find the right record?Send support the product name or batch code.
Contact supportProduct information
NAD+, clearly explained.
A coenzyme every cell uses to transfer energy and support core metabolic reactions.
Overview
NAD+ is essential to normal cell biology, but that does not automatically prove that delivering more NAD+ creates broad wellness or anti-aging effects. Direct-infusion research is still limited and much smaller than the surrounding marketing suggests.
Nicotinamide adenine dinucleotide (NAD+) is an essential cellular coenzyme involved in redox reactions and a substrate for enzymes linked to DNA repair and signalling. Established cellular importance does not automatically validate a wellness intervention.- Format
- Vial
- Available strengths
- 500mg
- Batch
- NAD 007-013
- Purity
- 99.6%
Specifications
Product details
- Sequence / identity
- Confirm in batch record
- Molecular formula
- C21H27N7O14P2
- Molecular weight
- 663.43 g/mol
- Storage and handling
- Protect from light and moisture. Follow the batch-specific handling record.
Review the analytical record connected to this exact batch.
- Batch
- NAD 007-013
- Purity
- 99.6%
Health Canada lists the named compound or components among unauthorized injectable drugs identified in the Canadian market. A research-use label does not make an unauthorized product suitable or legal for personal use.
Explore the research
What has been studied?
Check what was studied, what researchers observed, and the limitation attached to each finding.
Cellular redox and energy metabolism
NAD+/NADH couples are central to metabolic reactions across cells and tissues.
Evidence so far: Established biochemistryDirect intravenous NAD+
A small pilot traced plasma and urinary metabolites during a six-hour infusion but did not test clinical efficacy.
Evidence so far: Very limited human pharmacokineticsNAD+ as an aging biomarker
A 2026 multi-cohort analysis found whole-blood NAD+ was stable with age and across lifestyle interventions, challenging a common assumption.
Evidence so far: Human biomarker evidenceProposed mechanism
How researchers are investigating the mechanism.
NAD+ cycles between oxidized and reduced forms during energy metabolism. Cells also consume NAD+ through enzymes such as sirtuins, PARPs and CD38. Route and precursor choice materially affect absorption and metabolism.
Study records
What was studied—and what was not.
See what researchers tested, what they observed and the limitation attached to each result.
Study 01Open pilot tracking metabolites during a six-hour intravenous NAD+ infusion
- What researchers saw
- The study described plasma clearance and urinary metabolite patterns.
- Why that is not the whole story
- It did not establish a health benefit, optimal protocol or long-term safety.
Study 02Seven-cohort human analysis using validated mass spectrometry
- What researchers saw
- Investigators reported stable whole-blood NAD+ across age and lifestyle interventions.
- Why that is not the whole story
- Whole-blood levels are not equivalent to tissue-specific biology, but they challenge simple deficiency narratives.
Evidence gaps
What remains unknown?
- Clinical efficacy of direct NAD+ infusion for anti-aging, energy, cognition or recovery is not established by the pilot evidence.
- Blood NAD+ is not a validated universal measure of biological aging or tissue NAD+ status.
- Precursor studies cannot be treated as direct evidence for externally administered NAD+.
Primary sources
Check the original sources.
- Direct-infusion pilotGrant et al. Human plasma and urine NAD+ metabolome during a six-hour infusion. Front Aging Neurosci. 2019. PMID 31572171.
- Human biomarker studyTrętowicz et al. Whole-blood NAD+ across age and lifestyle interventions. Nat Metab. 2026. PMID 42135539.
- Tolerability evidenceReyna et al. Retrospective NAD+ versus NR infusion pilot. Front Aging. 2026. PMID 41704678.